Skip to content

Bio-Techne Corp

TECH· NasdaqCore metricsCIK 842023

Biological products, except diagnostic substances175 peers

Last sale
Nov 6, 2026 · +0.17%
Market cap
$11.44B
157.09M shares
Filings
1,054
$299.71M
Q1 2027−0.4% FY26 yoy
$28.29M
Q1 2027+147.8% FY26 yoy
$36.60M
Q1 2027+146.3% FY26 yoy
$67.20M
Q1 2027derived+2.6% FY26 yoy
$0.18
Q1 2027+152.2% FY26 yoy
$350.04M
Q1 2027+63.2% FY26 yoy
$11.44B
66.5×
9.3×
5.3×
2.69%
0.44%

Twelve months to Sep 30, 2026 · derived

Price

$72.80+21.45%+$12.86past year
Nov 6, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$1.22BFY 2026
$1.22B0FY 2015FY 2020FY 2026
PeriodEndedValueKindSource trail
FY 20262026-06-30$1,215,039,000reported
FY 20252025-06-30$1,219,635,000reported
FY 20242024-06-30$1,159,060,000reported
FY 20232023-06-30$1,136,702,000reported
FY 20222022-06-30$1,105,599,000reported
FY 20212021-06-30$931,032,000reported
FY 20202020-06-30$738,691,000reported
FY 20192019-06-30$714,006,000reported
FY 20182018-06-30$642,993,000reported
FY 20172017-06-30$563,003,000reported
FY 20162016-06-30$499,023,000reported
FY 20152015-06-30$452,246,000reported

Capital returns

Dividends and buybacks · FY2015 to FY2026
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2026$49.92M$41.68M$91.59M$0.32157.06M sh+1.0%34.8%
FY2025$50.39M$275.73M$326.12M$0.32155.55M sh−1.9%127.1%
FY2024$50.42M$80.04M$130.46M$0.32158.60M sh+0.3%55.3%
FY2023$50.29M$19.56M$69.85M$0.32158.17M sh+303.4%32.3%
FY2022$50.19M$160.95M$211.14M$0.3239.21M sh+0.3%75.3%

Segments

Revenue by Segments, FY2019 to FY2026FY2019Protein Sciences · FY2019 · $543.16MDiagnostics and Genomics · FY2019 · $171.67MFY2020Protein Sciences · FY2020 · $555.35MDiagnostics and Genomics · FY2020 · $184.55MFY2021Protein Sciences · FY2021 · $704.56MDiagnostics and Genomics · FY2021 · $227.74MFY2022Protein Sciences · FY2022 · $832.31MDiagnostics and Genomics · FY2022 · $274.84MFY2023Protein Sciences · FY2023 · $845.75MDiagnostics and Spatial Biology · FY2023 · $292.60MDiagnostics and Genomics · FY2023 · $292.60MFY2024Protein Sciences · FY2024 · $830.90MDiagnostics and Spatial Biology · FY2024 · $326.39MDiagnostics and Genomics · FY2024 · $326.39MOther Revenues from Business Held for Sale · FY2024 · $4.15MFY2025Protein Sciences · FY2025 · $870.25MDiagnostics and Spatial Biology · FY2025 · $346.26MFY2026Protein Sciences · FY2026 · $874.62MDiagnostics and Spatial Biology · FY2026 · $336.37M
LineFY2026ShareChange
Protein Sciences$874.62M72%+0.5%
Diagnostics and Spatial Biology$336.37M28%−2.9%
Diagnostics and Genomics———
Other Revenues from Business Held for Sale———
Total$1.22B

From the 10-K filed Aug 24, 2026TECH

Biological products, except diagnostic substances

Bio-Techne Corp is the 9th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Bio-Techne Corp · CIK 842023 · Engraved from SEC EDGAR